J&J's Imbruvica delivers solid response in relapsed CLL; Teva teams with Eagle to market new cancer med;

> Johnson & Johnson ($JNJ) unveiled positive results for Imbruvica in a small trial in high-risk leukemia patients; patients had failed on other therapies, but 88% responded to the J&J drug. Story

> Teva Pharmaceutical ($TEVA) signed up to promote an as-yet-to-be-approved cancer drug from Eagle Pharmaceuticals in the U.S.; EP-3102 is a potential rival to Teva's own Treanda. Article

> A U.S. judge said he would weigh other False Claims Act court decisions and consider reviving an off-label marketing case against Bayer Pharma. Report (reg. req.)

> Teva Pharmaceutical rolled out its generic versions of two injectable drugs, the blood thinner Lovenox and antibiotic Zyvox. News

> Bayer's Stivarga will lead the pack of new colon cancer drugs in China, GlobalData analysts say, with peak sales of $291 million in that market. More

And Finally... Roche ($RHHBY) is teaming up with Qualcomm ($QCOM) on remote health monitoring to gather patient data and help it track treatment results. Report

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.